DE-CSC
15.11.2022 15:01:43 CET | Business Wire | Press release
CSC, an enterprise-class domain registrar and world leader in mitigating domain and domain name system (DNS) threats, today released its third annual Domain Security Report that found three out of four Forbes Global 2000 companies have not adopted key domain security measures—exposing them to high risk of security threats. These companies have implemented less than half of all domain security measures.
In addition, lookalike domains are targeting those companies as well—with 75% of homoglyph registrations being registered to unrelated third parties. That means many of the world’s largest brands contend with maliciously registered domains that look like their brands. The intent of these fake domain registrations is to leverage the trust placed on the targeted brand to launch phishing attacks or other forms of digital brand abuse, or IP infringement that leads to revenue loss, traffic diversion, and a diminished brand reputation. Homoglyph domains are just some of the endless domain spoofing tactics and permutations that can be used by phishers and malicious third parties.
Additional key takeaways from CSC’s research include:
-
137 companies (6.8%) had a domain security score of “0”
Not deploying any of the recommended domain security measures puts these companies at risk for a variety of attacks, including but not limited to domain and DNS hijacking attacks, network and data breaches, phishing and ransomware attacks, and business email compromise (BEC).
-
45% of companies that use enterprise-class domain registrars also deploy registry lock
Registry lock is a highly cost-effective means to protect domain names against accidental or unauthorized modifications or deletions. Only 5% of companies that use consumer-grade registrars have registry lock deployed. Additionally, only six organizations within the Global 2000 had the highest overall domain security score, which correlates with their use of an enterprise-class registrar.
-
DMARC is the only domain security measure with significantly increased adoption this year
Given all the news about phishing attacks—including their increase in volume and complexity—it’s no surprise that domain-based message authentication, reporting, and conformance (DMARC) adoption has increased by 12 percentage points in the last 12 months. However, growth in other domain security measures, such as registry lock, domain name system (DNS) redundancy, DNS security extensions (DNSSEC), and certificate authority authorization (CAA) records saw limited increases year-over-year.
“This report shows that while some progress has been made, a majority of the companies listed in the Forbes Global 2000 are still overlooking full implementation of foundational domain security measures,” says Mark Calandra, president of CSC’s Digital Brand Services. “A focus on securing legitimate domains while monitoring for malicious domains in parallel needs to be a bigger priority for companies that are advocating for a Zero Trust model to stay protected and thwart cyber risk. Otherwise, companies are exposing themselves to significant enterprise risks that can impact their cyber security posture, data protection, intellectual property, supply chains, consumer safety, revenue, and reputation.”
CSC’s report also found that 82% of the third parties registering homoglyph domains are actively masking their identity. This demonstrates the attempt to hide their ownership, showing they may have some nefarious intentions. Additionally, 48% have MX records in 2022, compared to 43% in 2021. MX records can be used to send phishing emails or to intercept email.
To learn more about CSC’s approach to domain security, visit cscdbs.com. Download the Domain Security Report now at cscdbs.com/securityreport.
About CSC
CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known cybersecurity oversights that exist, and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss, and significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
